NYXH Nyxoah SA
Price Chart
Executive Summary
Nyxoah filed a preliminary prospectus supplement (424B5) for an underwritten follow-on offering of ordinary shares, with pricing to be determined after the June 3, 2026 closing price of $2.85/share. The offering size is undisclosed. The company disclosed a cash runway extending only into Q3 2026, an accumulated deficit of €321.7M, and that its IPR petitions against Inspire were denied. Concurrently, the company announced a CEO transition to a U.S.-based successor, adding leadership uncertainty.
Actionable Insight
The diluted equity raise at a depressed price while cash runway only extends into Q3 2026 signals acute financing need. Combined with failed IPR petitions against Inspire and a CEO transition, the risk/reward is unfavorable for existing holders. Traders should expect further downside pressure as the offering prices and overhang materializes.
Key Facts
- 424B5 filing for an underwritten follow-on public offering of ordinary shares; share count, price, and gross proceeds are all undisclosed placeholder amounts.
- Stock price at last sale on Nasdaq was $2.85 on June 3, 2026, down ~75% from the $11.33 reference price in the base prospectus from April 1, 2025.
- Cash, cash equivalents, and financial assets totaled €25.9M as of March 31, 2026; accumulated deficit was €321.7M.
- Cash runway expected only into Q3 2026, even after drawing the second tranche of the €13.8M EIB loan.
- IPR petitions against Inspire Medical Systems' patents were denied institution on April 14, 2026, weakening Nyxoah's litigation position.
- CEO Olivier Taelman is transitioning out; a search for a U.S.-based CEO has been launched, creating leadership uncertainty during a capital raise.
- Existing stockholders affiliated with directors have indicated non-binding interest in purchasing shares.
- Underwriters granted a 30-day over-allotment option; 90-day lock-up for company, directors, and officers.
Financial Impact
Undisclosed offering size; at the $2.85 reference price, investors face immediate and substantial dilution given negative tangible book value of -$0.36/share.
Risk Factors
- Significant dilution from the offering at a low stock price; net tangible book value is already negative.
- Cash runway only into Q3 2026 suggests another capital raise will be needed soon after this one.
- Denied IPR petitions weaken Nyxoah's defense against Inspire's patent infringement lawsuit, increasing legal overhang.
- CEO transition adds execution risk during a critical commercial ramp in the U.S.
- Reimbursement and coding uncertainty for the Genio system remains a headwind to U.S. adoption.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-070509 |
| Document: 0001104659-26-070509-index-headers.html | 0001104659-26-070509 |
| Document: 0001104659-26-070509-index.html | 0001104659-26-070509 |
| Document: 0001104659-26-070509.txt | 0001104659-26-070509 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
6-K
| $1.49 awaiting T+5 | awaiting T+5 | — | $1.39 (+6.40%) |
|
Jun 8, 2026
4d ago
|
6-K
| $1.36 awaiting T+5 | awaiting T+5 | — | $1.39 (−2.21%) |
|
Jun 8, 2026
4d ago
|
424B5
| $1.69 awaiting T+5 | awaiting T+5 | — | $1.39 (+17.75%) |
|
Jun 5, 2026
7d ago
|
Press Release
| $1.59 awaiting T+5 | awaiting T+5 | — | $1.39 (+12.58%) |
|
Jun 4, 2026
8d ago
|
424B5
| $1.73 awaiting T+5 | awaiting T+5 | — | $1.39 (+19.65%) |
|
May 20, 2026
23d ago
|
Press Release
| $2.87 $2.99 | ▲ +4.18% | ▲ +2.58% | $1.39 (−51.57%) |
|
May 12, 2026
4w ago
|
Press Release
| $3.08 $2.81 | ▼ −8.77% | ▼ −7.61% | $1.39 (−54.87%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −6.29% | $1.39 (−54.87%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $3.74 $3.14 | ▼ −16.04% | ▼ −14.51% | $1.39 (−62.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access